Literature DB >> 375485

Treatment of vivax malaria with sulfadoxine-pyrimethamine and with pyrimethamine alone.

E B Doberstyn, C Teerakiartkamjorn, R G Andre, P Phintuyothin, S Noeypatimanondh.   

Abstract

The effect of pyrimethamine and the combination of pyrimethamine-sulfadoxine (Fansidar) upon the termination of the acute attack of vivax malaria was studied in Thailand. Pyrimethamine was found to be ineffective, providing clearance of parasitaemia in only two of six patients by the end of seven days following treatment. The combination, administered in a two-tablet single dose (sulfadoxine 1 gm, pyrimethamine 50 mg) eliminated parasitaemia in only six of ten patients within seven days. Three tablets (sulfadoxine 1 . 5 gm, pyrimethamine 75 mg) given to 11 patients, provided clearance of parasitaemia in all within seven days; however, mean parasite and fever clearance times in this group were prolonged at 90 and 50 hours respectively. Chloroquine remains the drug of choice for the termination of the acute attack of vivax malaria. Subsequent primaquine is necessary for the prevention of relapse.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 375485     DOI： 10.1016/0035-9203(79)90121-4

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN： 0035-9203            Impact factor:   2.184


  7 in total

1.  An evaluation of five regimens for the outpatient therapy of falciparum malaria in Thailand 1980-81.

Authors:  S Pinichpongse; E B Doberstyn; J R Cullen; L Yisunsri; Y Thongsombun; K Thimasarn
Journal:  Bull World Health Organ       Date:  1982       Impact factor: 9.408

2.  Defining the role of mutations in Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene using an episomal Plasmodium falciparum transfection system.

Authors:  Alyson M Auliff; John H Adams; Michael T O'Neil; Qin Cheng
Journal:  Antimicrob Agents Chemother       Date:  2010-06-21       Impact factor: 5.191

3.  Different allele prevalence in the dihydrofolate reductase and dihydropteroate synthase genes in Plasmodium vivax populations from China.

Authors:  Miao Miao; Zhaoqing Yang; Long Cui; Jessica Ahlum; Yaming Huang; Liwang Cui
Journal:  Am J Trop Med Hyg       Date:  2010-12       Impact factor: 2.345

4.  Novel Plasmodium vivax dhfr alleles from the Indonesian Archipelago and Papua New Guinea: association with pyrimethamine resistance determined by a Saccharomyces cerevisiae expression system.

Authors:  Michele D Hastings; Jason D Maguire; Michael J Bangs; Peter A Zimmerman; John C Reeder; J Kevin Baird; Carol Hopkins Sibley
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

5.  Sulfadoxine resistance in Plasmodium vivax is associated with a specific amino acid in dihydropteroate synthase at the putative sulfadoxine-binding site.

Authors:  Michael Korsinczky; Katja Fischer; Nanhua Chen; Joanne Baker; Karl Rieckmann; Qin Cheng
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

6.  Efficacy of Pyrimethamine/Sulfadoxine versus Chloroquine for the Treatment of Uncomplicated Falciparum Malaria in Children Aged Under 5 Years.

Authors:  W Zheng; H Jiang; Z Xiong; Z Jiang; H Chen
Journal:  Iran J Parasitol       Date:  2013-01       Impact factor: 1.012

7.  Functional analysis of Plasmodium vivax dihydrofolate reductase-thymidylate synthase genes through stable transformation of Plasmodium falciparum.

Authors:  Alyson M Auliff; Bharath Balu; Nanhua Chen; Michael T O'Neil; Qin Cheng; John H Adams
Journal:  PLoS One       Date:  2012-07-09       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.